Top 10 Contrast Media Companies

Why Contrast Media Market Are Expanding?

The contrast media market is witnessing steady expansion driven by demand, rising from USD 7.06 billion in 2025 to an estimated USD 11.24 billion by 2035, showing a Compound Annual expansion Rate (CAGR) of 4.76% throughout the forecast period. The Market Research Future (MRFR) report reveals that the diagnostic imaging market is driven by two main demand engines, the increasing global burden of chronic disease – cardiovascular disease, oncology, and neurological disease accounting for the bulk of diagnostic imaging referrals – and the structural growth of diagnostic imaging infrastructure in mature as well as high-growth markets.

According to WHO, cardiovascular disease accounts for 17.9 million fatalities per year while cancer accounts for roughly 10 million globally. This maintains a high and growing imaging volume that directly translates into contrast agent consumption. 

North America is the leading region with a global revenue share of over 45% in 2024. This is attributed to advanced imaging infrastructure and volumes recorded by the CDC with more than 80 million CT scans per year in the United States alone. Europe is home to a population of aged 60 years and over, which is roughly 25% (WHO).

The region is valued at USD 2.02 billion in 2024 and holds a 30% share, supporting high imaging rates. Asia-Pacific is the most active growth frontier, with an estimated 20% share, driven by China and India infrastructure investment. The FDA and EMA support for next-generation contrast agent approvals and the increasing preventive healthcare culture worldwide will maintain the growth of compounds at a rate higher than the market during the projection period to 2035, MRFR predicts.

Why These Companies Are Leading the Market?

MRFR identifies four structural factors that separate category leaders in the Contrast Media Market: proprietary molecular innovation in contrast agent chemistry, global manufacturing and supply chain scale, clinical validation depth across imaging modalities, and disciplined geographic expansion strategies targeting high-growth emerging markets.

Molecular innovation defines the competitive hierarchy. Bayer AG leads through its Radiology division’s gadolinium-based and iodinated agent portfolio — including Ultravist and Gadovist — backed by decades of chemistry investment and clinical validation across cardiovascular, oncology, and neurological indications. Manufacturing scale gives GE Healthcare a structural advantage through its Pharmaceutical Diagnostics division, which commands the global iodine supply chain following its long-term iodine supply agreement with SQM Chile, securing production of an additional 30 billion doses annually by 2025.

Top 10 Global Contrast Media Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading contrast media companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

Detailed Company Profiles

1. Bayer AG | XETRA: BAYN | Leverkusen, Germany

Company Overview. Bayer AG is the dominant global leader in contrast media through its Radiology business unit within Pharmaceuticals, delivering the world’s most widely prescribed gadolinium-based contrast agent (GBCA), Gadovist (gadobutrol), alongside the established non-ionic iodinated agent Ultravist (iopromide), collectively deployed in CT, MRI, and angiographic procedures across more than 100 countries.

The Radiology portfolio additionally encompasses Primovist (gadoxetate disodium), a liver-specific GBCA used for hepatocellular carcinoma characterization, and Magnevist, a linear GBCA for legacy MRI applications. In January 2025, Bayer reported positive topline results from the Phase III clinical development program for gadoquatrane, its next-generation macrocyclic GBCA targeting reduced doses while maintaining diagnostic quality. Bayer’s Radiology business continued to post strong gains in 2024 and 2025, fueled by higher volumes for Ultravist and CT Fluid Delivery. Explore Bayer’s radiology portfolio at radiology.bayer.com.

2. GE Healthcare | NASDAQ: GEHC | Chicago, Illinois, USA

Company Overview. GE Healthcare’s Pharmaceutical Diagnostics (PDx) division is the world’s largest manufacturer of iodinated contrast media by volume, producing Omnipaque (iohexol) and Visipaque (iodixanol) — the latter being the only iso-osmolar non-ionic iodinated agent on the market — alongside the ultrasound contrast agent Optison. The PDx division generated approximately USD 2.51 billion in FY2024 revenue (up 9% year-over-year, per GE Healthcare Q4 2024 earnings release, February 13, 2025).

The division’s global iodine supply chain is underpinned by a landmark long-term agreement with Sociedad Quimica y Minera (SQM) de Chile, the world’s largest iodine producer, securing raw material supply for the production of an additional 30 billion doses of iodine contrast media per year by 2025. GE Healthcare invested USD 138 million in its Cork, Ireland manufacturing facility to address increasing contrast media demand, as announced in its FY2024 results. Visit GE Healthcare’s pharmaceutical diagnostics portfolio at gehealthcare.com.

3. Bracco Imaging S.p.A. | Private | Milan, Italy

Company Overview. Bracco Imaging S.p.A. is a specialty contrast media leader with particular depth in ultrasound and MRI contrast modalities, delivering SonoVue (sulfur hexafluoride microbubbles) — the leading ultrasound contrast agent globally — alongside the macrocyclic GBCA ProHance (gadoteridol) and the iodinated agent Isovue (iopamidol) for CT and angiographic procedures.

Bracco serves hospital radiology departments, echocardiography units, and gastrointestinal imaging centers across more than 90 countries, with a clinical differentiation strategy centered on superior safety profiles for renally compromised patients. Market Research Future identifies Bracco’s specialized ultrasound and MRI portfolios as strategically positioned to capture disproportionate share as healthcare systems shift toward radiation-free diagnostic modalities. Explore Bracco’s contrast agent portfolio at bracco.com/products-services.

4. Guerbet Group | Euronext Paris: GBT | Villepinte, France

Company Overview. Guerbet Group is a specialty contrast media company with a focused portfolio spanning gadolinium-based MRI agents, iodinated CT agents, and digital imaging workflow solutions, delivering Dotarem (gadobutrol), one of the most widely prescribed macrocyclic GBCAs globally, alongside Xenetix (iobitridol) for CT imaging.

Guerbet’s FY2024 full-year revenue was EUR 841.1 million, up 9.0% at constant exchange rates, reflecting strong momentum in the Americas (+20.5%) and Asia (+10.1%) (per Guerbet full-year 2024 results press release, March 26, 2025). 

5. Lantheus Medical Imaging | NASDAQ: LNTH | Bedford (North Billerica), Massachusetts, USA

Company Overview. Lantheus Medical Imaging is the leading radiopharmaceutical and contrast media specialist in the United States, with a commercial portfolio spanning Definity (perflutren lipid microspheres) for cardiac ultrasound enhancement and PYLARIFY (piflufolastat F 18) for PSMA PET imaging in prostate cancer staging.

Lantheus reported full-year 2024 worldwide revenue of USD 1.53 billion, a 10.5% increase year-over-year, with PYLARIFY exceeding USD 1 billion in net sales to become the first-ever blockbuster radiodiagnostic (per Lantheus Q4/FY2024 earnings release, February 26, 2025). 

6. Siemens Healthineers | XETRA: SHL | Erlangen, Germany

Company Overview. Siemens Healthineers participates in the Contrast Media Market through its proprietary Imeron (iomeprol) iodinated contrast agent portfolio and, more strategically, through its advanced contrast injection systems and AI-powered imaging software that determine protocol parameters governing agent selection, dose, and administration timing across CT and MRI platforms. Total company revenue for fiscal year 2024 (ended September 30, 2024) was EUR 22.4 billion, up 4.7% year-over-year. 

7. Fujifilm Holdings Corporation | TSE: 4901 | Tokyo, Japan

Company Overview. Fujifilm Holdings participates in the Contrast Media Market through its Medical Systems and Life Sciences division, supplying iodine-based CT contrast agents — principally IOPAMIRON (iopamidol) — for computed tomography and angiographic procedures across Asia-Pacific hospital networks, with commercial distribution extending to over 60 countries primarily through regional pharmaceutical partnerships.

Fujifilm’s contrast agent business is integrated within a broader diagnostic imaging strategy that encompasses CT and digital radiography systems, PACS software, and endoscopy. Market Research Future recognizes Fujifilm’s Asia-Pacific distribution network as a structural advantage in the region’s fastest-growing contrast media geography. Visit Fujifilm’s medical solutions at fujifilm.com/global/en/healthcare.

8. Canon Medical Systems Corporation | Private (Canon subsidiary) | Otawara, Japan

Company Overview. Canon Medical Systems Corporation — the renamed Toshiba Medical Systems — serves the Contrast Media Market primarily through AI-powered contrast injection protocol optimization software embedded within its CT and MRI imaging console platforms, delivering patient-specific contrast administration guidance across Canon Medical system installations in more than 80 countries worldwide.

The company’s Vitrea Advanced Visualization software and Aquilion CT platform include integrated contrast timing and bolus tracking tools that optimize iodinated agent utilization in CT angiography and dynamic CT perfusion examinations. Canon Medical Systems is a wholly owned subsidiary of Canon Inc. Explore Canon Medical’s imaging platform at global.medical.canon.

9. Bristol-Myers Squibb Company | NYSE: BMY | New York, USA

Company Overview. Bristol-Myers Squibb’s historical participation in the Contrast Media Market centered on its Cardiolite (technetium Tc-99m sestamibi) nuclear cardiology imaging agent and legacy radiopharmaceutical portfolio, which served nuclear medicine departments globally for myocardial perfusion imaging.

BMS subsequently divested its contrast media and pharmaceutical diagnostics assets as part of a strategic refocusing on oncology and immunology therapeutics, with key contrast media intellectual property and commercial arrangements transitioning to Bracco Imaging and Lantheus Medical Imaging through licensing and acquisition.

10. Hoffmann-La Roche Ltd | SIX: ROG | Basel, Switzerland

Company Overview. Hoffmann-La Roche Ltd participates in the Contrast Media Market through Roche Diagnostics’ molecular imaging and diagnostics integration strategy, focusing on companion diagnostic imaging agents and specialty PET tracers aligned with its oncology drug development pipeline, rather than conventional iodinated or gadolinium-based contrast agent manufacturing at commercial scale.

Roche’s imaging diagnostics participation centers on enabling precision oncology workflows — integrating molecular imaging data with biomarker-driven patient selection for targeted therapies — across more than 100 countries served by its global diagnostics division. Explore Roche Diagnostics at diagnostics.roche.com.

M&A Activity Tracker (2022–2026)

The Contrast Media Market has undergone targeted consolidation as established pharmaceutical diagnostics companies pursue inorganic growth to expand modality coverage, geographic reach, and supply chain resilience. Market Research Future tracks the following verified transactions directly relevant to the contrast media market. Note: The original report incorrectly listed “Lantheus Medical / POINT Biopharma (radiopharmaceuticals) / USD 1.44B acquisition” under 2024. This has been corrected: Lantheus entered a licensing agreement with POINT Biopharma in 2022 for USD 260M upfront (up to USD 2B in total milestones). POINT Biopharma the company was acquired by Eli Lilly in December 2023 for approximately USD 1.44B — not by Lantheus. The table below reflects these validated facts.

Key Trend. MRFR analysis identifies supply chain security and molecular imaging portfolio expansion as the dominant M&A themes in the Contrast Media Market, with acquirers prioritizing radiopharmaceutical pipeline assets and emerging-market distribution capabilities that accelerate growth beyond the mature iodinated and gadolinium-based agent segments.

R&D Investment & Innovation Signals

R&D investment across the Contrast Media Market has increased materially in 2025–2026 as manufacturers race to close the gap between agent safety in high-risk patient populations and growing imaging volume demands, while simultaneously integrating AI and digital workflow tools that differentiate agent administration from commoditized bulk supply. Market Research Future tracks the following verified 2025–2026 R&D and technology programs from official company sources:

• Bayer AG reported positive topline results from the Phase III clinical development program for gadoquatrane in January 2025, a next-generation macrocyclic GBCA targeting reduced doses that maintain diagnostic image quality in patients with eGFR below 45 mL/min/1.73m², addressing the largest unmet clinical need in MRI contrast administration across chronic kidney disease populations globally.
• GE Healthcare has invested in its Pharmaceutical Diagnostics manufacturing science platform, scaling production of Visipaque (iodixanol) — the only iso-osmolar iodinated contrast agent — with enhanced formulation stability for high-temperature storage in Asia-Pacific and Middle Eastern distribution environments, alongside a USD 138M investment in its Cork, Ireland facility announced with FY2024 results.
• Bracco Imaging has developed SonoVue AI-enhanced acquisition protocols in collaboration with ultrasound OEM partners, embedding automated microbubble perfusion quantification into clinical workstations to expand the diagnostic utility of ultrasound contrast beyond conventional echocardiography into liver, kidney, and oncological tumor characterization.
• Guerbet launched its CLARIVY AI platform in 2025, a cloud-based contrast protocol optimization engine that integrates with hospital RIS and PACS systems to generate patient-specific Dotarem dose recommendations based on body weight, indication, and renal function parameters, deployed across 12 major European radiology networks.
• Lantheus Medical Imaging advanced its radiopharmaceutical manufacturing capacity program in 2025, commissioning a USD 75 million GMP production expansion at its North Billerica facility to increase PYLARIFY (piflufolastat F 18) throughput by 30%, addressing PSMA PET scan demand growth driven by expanding prostate cancer staging guidelines.